Enanta Pharmaceuticals Inc. (ENTA), a clinical-stage biotechnology company focusing on viral infections and immunological diseases, will be highlighting its investigational programs - Zelicapavir and EPS-3903 - at the American Thoracic Society (ATS) International Conference today.
Zelicapavir, an oral, direct-acting antiviral specifically targeting the N-protein, is being developed for the treatment of respiratory syncytial virus. As an N-protein inhibitor, Zelicapavir directly disrupts the ability of the virus to replicate, as compared to fusion inhibitors that work by preventing cells from becoming infected while allowing viral replication to continue.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com